277 related articles for article (PubMed ID: 7482412)
21. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
[TBL] [Abstract][Full Text] [Related]
22. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
23. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J
Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424
[TBL] [Abstract][Full Text] [Related]
24. Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.
Daniel WC; Meidell RS; Hillis LD; Lange RA
Coron Artery Dis; 1996 Jan; 7(1):45-9. PubMed ID: 8773432
[TBL] [Abstract][Full Text] [Related]
25. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
[TBL] [Abstract][Full Text] [Related]
26. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
Bellucci S; Ignatova E; Jaillet N; Boffa MC
Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
[TBL] [Abstract][Full Text] [Related]
27. Effects of direct percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors.
Saito M; Nakabayashi T; Iuchi K; Ishikawa T; Kaseno K; Yoshida T; Asakura H; Matsuda T
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):801-4. PubMed ID: 7507363
[TBL] [Abstract][Full Text] [Related]
28. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
29. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
[TBL] [Abstract][Full Text] [Related]
30. Endothelial cell activation in cutaneous vasculitis.
Jurd KM; Stephens CJ; Black MM; Hunt BJ
Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
[TBL] [Abstract][Full Text] [Related]
31. The kinetics of plasmin inhibition by aprotinin in vivo.
Kang HM; Kalnoski MH; Frederick M; Chandler WL
Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
[TBL] [Abstract][Full Text] [Related]
32. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
33. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
[TBL] [Abstract][Full Text] [Related]
34. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
[TBL] [Abstract][Full Text] [Related]
35. Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Levi M; Lensing AW; Büller HR; Prandoni P; Dooijewaard G; Cuppini S; ten Cate JW
Thromb Haemost; 1991 Oct; 66(4):426-9. PubMed ID: 1796391
[TBL] [Abstract][Full Text] [Related]
36. [Tissue plasminogen activator (t-PA) in aqueous humor of patients with cataract].
Kotschy M; Kałuzny J; Kaniasty M; Zekanowska E; Kropińska E
Klin Oczna; 1996 Mar; 98(3):201-3. PubMed ID: 9019589
[TBL] [Abstract][Full Text] [Related]
37. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
38. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
40. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]